Introduction
MM is a common type of malignant plasma cell disorders. In Western countries, MM accounts for about 0.9% of all cancer deaths, and for about 10% of burdens of hematological malignancies. 1, 2 Over the past decade, the novel agents such as thalidomide, 3 bortezomib, 4 ,5 and lenalidomide 6, 7 have significantly improved the response rate and survival in patients with MM. [8] [9] [10] Induction therapy followed by HDT (traditionally, high-dose melphalan) and ASCT is considered standard of care for NDMM patients aged <65 years. 11 Until now, there are many Phase III RCTs reporting diverse induction regimens containing novel agents, such as the GIMEMA, 12 MRC Myeloma IX trial, 13 and HOVON-50.
14 However, certain issues should be noted. First, some induction regimens have not yet been compared in a direct manner in RCTs. Second, a comprehensive evaluation and ranking for all available regimens have not yet been established with respect to the early efficacy and survival measures.
Study selection
The following selection criteria were used to evaluate the eligibility of references identified by the literature search: 1) RCT design; 2) the participants were transplant-eligible patients with newly diagnosed MM; 3) the studies compared different pre-ASCT induction therapies; and 4) the data of investigative outcome measures (ORR, PFS, or OS) were provided or could be calculated.
Outcome measures
The study end point was post-induction ORR (an objective response equal to or better than PR [≥PR] ), OS (the time from randomization to the date of death), and PFS (the time from the start of the treatment to disease progression or death). The definition of PR and progression followed the International Myeloma Working Group Uniform Response Criteria. 18 
Data extraction
We utilized predesigned data extraction form to guide the data extraction process. We extracted patients' baseline characteristics, outcomes, and number of events. For some trials in which the HR and its 95% CI for OS and PFS were not reported but the relevant data for imputation were provided, Tierney et al's method 19 was used for calculation. Besides, we reconstructed IPD using Guyot et al's 20 method and performed survival analysis to make a comparison between TAD and VTD in terms of OS, based on extracted arm data from two independent trials. 21, 22 All the abovementioned procedures were independently accomplished by two researchers (Z-HZ and J-FC). If any discrepancies were found, a third researcher (Y-XL) will be involved in discussing.
Statistical analysis
For ORR, we calculated the natural logarithmic OR and its SE as the effect size and precision measure input into the NMA model. For OS and PFS, the natural logarithmic of HR and its SE were utilized. The consistency of effect sizes among studies was assessed by I 2 statistic indicating heterogeneity among individual studies. 23 When the value of I 2 ≤ 50%, we would apply fixed-effects model. Otherwise, the random-effects model would be used. Visualization of analysis results including the forest plot and rankogram was performed. All the statistical analyses were made using the R software version 3.2.5.
Results

Inclusion and basic characteristics of eligible studies
A total of 1,472 articles were obtained through our initial literature search, and 1,458 of these articles were excluded due to reasons indicated ( Figure 1 ). Our NMA finally included 14 RCTs (full texts available for 13 studies  12,14,21,22,24-32 and  one conference abstract   33 ). Details of induction regimens of included RCTs are provided in Table 1 . A total of 4,763 patients were included in the NMA. In total, there were 14 induction regimens, by which 17 pairwise comparisons were established ( Figure 2 ). Only two trials included multiple arm, 26, 32 and others included two arms. 12, 14, [21] [22] [23] [24] [25] [27] [28] [29] [30] [31] 33 All 14 trials reported ORR outcome, but eight out of 14 trials reported OS and PFS outcome, respectively. The baseline characteristics of patients from each trial, including gender, median age, International Staging System stage, median β2-microglobulin, median albumin, and types of M protein, are provided in Table 2 .
Risk of bias assessment
The Cochrane Collaboration's tool for assessing the risk of bias was used to evaluate the quality of the included trials, 
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Induction regimens for transplant-eligible myeloma patients except for one conference abstract. 33 The results are shown in Figure 3 . The included RCTs had low risks of selection bias about random sequence generation, attrition bias, reporting bias, and other biases, in which the rates of low risk were 100%, 92.3%, 92.3%, and 76.9%, respectively. Studies without clear information on allocation concealment, performance bias and detection bias accounted for 53.8%, 92.3%, and 92.3%, respectively.
ORR
A total of 13 included trials were able to be used to evaluate ORR with NMA. 12, 14, 22, [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] We selected the fixed-effects model due to nonsignificant heterogeneity (I 2 = 24%). The forest plot with Cy-Dex as the reference is shown in Figure 4 . For the pairwise comparison of regimens, VTD had significantly higher ORR than other regimes, except for VDCR and VDR to which the superiority was nonsignificant (Table S1) . VDR, VDCR, VDC, VD, VBMCP-VBAD-B, TD, RD, and PAD had significantly higher ORR than VAD, Dex, and Cy-Dex. TAD showed significantly higher ORR than Cy-Dex and VAD, but had significantly poorer ORR than PAD, VBMCP-VBAD-B, VDC, VDCR, VDR, and VTD. Meanwhile, VDCR had significantly higher ORR than VDR. VBMCP-VBAD-B resulted in significantly better ORR than VD and TD. No statistically significant difference was found for other comparisons. VTD was ranked the best regimen in terms of ORR according to rankogram which showed the rank probability ( Figure 5 ).
OS
Eight studies involving 10 regimens were included in NMA for OS. 12, 14, 21, 22, 24, 26, 29, 31 The data of VTD vs TAD were based on reconstructed IPD obtained by Guyot et al's 19 approach. According to the value of I 2 (1%), the fixed-effects model was used in NMA. Results showed that VTD was significantly better than TAD and VAD, and PAD was also significantly superior to VAD. Meanwhile, Cy-Dex had a shorter OS than the other nine regimens (Figure 4 ). On the other hand, there was no statistically significant difference among VTDC, Cy-Dex, Dex, VD, VBMCP-VBAD-B, PAD, VTD, and TD (Table S2) . VTDC was ranked the best regimen for OS with relatively higher probability ( Figure 5 ).
PFS
Eight out of 14 trials reported data on PFS. 12, 14, 21, [24] [25] [26] 29, 31 The fixed-effects model was used for NMA, because of the value of I 2 (18%). The forest plot of TAD vs other eight regimens is shown in Figure 4 . PAD, VD, VTD, VBMCP-VBAD-B, TAD, and VTDC had significant superiority when compared with TD (Table S3) . PAD, VD, VTD, VBMCP-VBAD-B, TAD, and VTDC had significantly better PFS than TD. Furthermore, TAD and PAD resulted in significantly better PFS than VAD. 
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Induction regimens for transplant-eligible myeloma patients VBMCP-VBAD-B had significantly better PFS than VTD. No statistically significant difference was found for other comparisons. TAD was ranked the best regimen for PFS with relatively higher probability ( Figure 5 ).
Discussion
Since the introduction of the proteasome inhibitor bortezomib and IMiDs such as thalidomide and lenalidomide, the novel agents have shown increased benefits compared with traditional regimens such as VAD regimen, the standard induction in the 1990s. 28, 29, 34 Two meta-analyses found that bortezomib-based induction regimens result in improvements in both PFS and OS, compared with nonbortezomib-based induction regimens, despite higher risk of toxicity. 35, 36 The better complete response, ORR, and PFS of velcade plus thalidomide-based regimens vs velcade-based or thalidomide-based regimens were also demonstrated in another meta-analysis. 37 In addition, three-drug induction regimens combining bortezomib and Dex became the standard of care for transplant-eligible NDMM patients in 2014, because of the better efficacy. 24, 26, 34, 38 To date, no comprehensive overall comparison involving multiple induction options has been realized yet. NMA, first proposed by Lumley, 15 can integrate direct and indirect evidence and make a global comparison of various regimens.
In our NMA, we found the superiority of VTD regimen for ORR. In GIMEMA and PETHEMA/GEM trial, Cavo et al 12 and Rosiñol et al 26 comparing VTD with TD showed significantly higher ORR for VTD. Meanwhile, reduced doses of VTD had higher ORR than VD, without statistical significance. 25 In IFM 2013-04 trial, VTD was significantly superior to VDC. 27 Although VTD resulted in an improvement in ORR when compared with VTDC, VTDC shows better performance in both PFS and OS in the NMA. For OS, VTDC is superior to others in our NMA. In a Phase II trial by Ludwig et al, 21 VTDC showed nonsignificant superiority compared to VTD (HR = 0.87, 95% CI: 0.44-1.72, P = 0.69). Interestingly, in our mixed comparisons, the same result was observed (HR = 0.87, 95% CI: 0.44-1.7). For the PFS outcome, TAD had a better PFS than the other eight regimens, including VTD (HR = 0.66, 95% CI: 0.39-1.1) and VTDC (HR = 0.91, 95% CI: 0.44-1.9). However, TAD showed the significant inferiority when compared with VTD in terms of ORR (OR = 0.21, 95% CI: 0.12-0.38) and OS (HR = 1.8, 95% CI: 1.0-3.1), and similar trend was found for the comparison of TAS vs VTDC in terms of OS (HR = 2.0, 95% CI: 0.85-4.9). According to our NMA, VTDC was considered as more beneficial regimen in survival, which was ranked as the best and second regimen for OS and PFS, respectively. VTD and TAD were also promising regimens for transplant-eligible NDMM patients, especially for VTD, which was ranked as the best and second regimen for ORR and OS. On the other hand, in addition to efficacy measures, toxicity profiles, which are not meta-analytically analyzed in this article, may also be of great importance for the choice of treatment. A meta-analysis found that bortezomib-based induction regimens increased the risk of adverse events with a grade ≥3, compared with nonbortezomib-based induction regimens (63% vs 59%). 36 Another meta-analysis showed that bortezomib-thalidomide-based regimens were linked to higher incidence of peripheral neuropathy than bortezomib-based regimens or thalidomide-based regimens (OR = 1.64, 95% CI: 0.77-3.46, P = 0.2). 37 Furthermore, apparent toxicity was observed for quadruple regimens in some trials. 21, 32 In further studies, a comprehensive analysis concerning toxicity will provide valuable information for decision-making.
There are some limitations of this NMA. First, many comparisons in the NMA were based on single study; Abbreviations: Cy-Dex, cyclophosphamide plus dexamethasone; NMA, network meta-analysis; PAD, bortezomib plus doxorubicin plus dexamethasone; RCTs, randomized controlled trials RD, lenalidomide plus dexamethasone; TAD, thalidomide plus doxorubicin plus dexamethasone; TD, thalidomide plus dexamethasone; VAD, vincristine plus doxorubicin plus dexamethasone; VBMCP-VBAD-B, BCNU plus vincristine plus melphalan plus prednisone plus dexamethasone plus bortezomib; VD, bortezomib plus dexamethasone; VDC, bortezomib plus dexamethasone plus cyclophosphamide; VDCR, bortezomib plus dexamethasone plus cyclophosphamide plus lenalidomide; VDR, bortezomib plus dexamethasone plus lenalidomide; VTD, bortezomib plus thalidomide plus dexamethasone; VTDC, bortezomib plus thalidomide plus dexamethasone plus cyclophosphamide. 33 (34) 43 (44) 21 ( 38 (24) 82 (52) 38 ( RD, lenalidomide plus dexamethasone; TAD, thalidomide plus doxorubicin plus dexamethasone; TD, thalidomide plus dexamethasone; VAD, vincristine plus doxorubicin plus dexamethasone; VBMCP-VBAD-B, BCNU plus vincristine plus melphalan plus prednisone plus dexamethasone plus bortezomib; VD, bortezomib plus dexamethasone; VDC, bortezomib plus dexamethasone plus cyclophosphamide; VDCR, bortezomib plus dexamethasone plus cyclophosphamide plus lenalidomide; VDR, bortezomib plus dexamethasone plus lenalidomide; VTD, bortezomib plus thalidomide plus dexamethasone; VTDC, bortezomib plus thalidomide plus dexamethasone plus cyclophosphamide.
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Figure 4
Forest plots comparing different induction treatments in terms of (A) the ORR, with Cy-Dex as the reference, (B) the OS, with Cy-Dex as the reference, and (C) the PFS, with TAD as the reference. Abbreviations: Cy-Dex, cyclophosphamide plus dexamethasone; Dex, dexamethasone; HR, hazard ratio; OR, odds ratio; ORR, overall response rate; OS, overall survival; PAD, bortezomib plus doxorubicin plus dexamethasone; PFS, progression-free survival; RD, lenalidomide plus dexamethasone; TAD, thalidomide plus doxorubicin plus dexamethasone; TD, thalidomide plus dexamethasone; VAD, vincristine plus doxorubicin plus dexamethasone; VBMCP-VBAD-B, BCNU plus vincristine plus melphalan plus prednisone plus dexamethasone plus bortezomib; VD, bortezomib plus dexamethasone; VDC, bortezomib plus dexamethasone plus cyclophosphamide; VDCR, bortezomib plus dexamethasone plus cyclophosphamide plus lenalidomide; VDR, bortezomib plus dexamethasone plus lenalidomide; VTD, bortezomib plus thalidomide plus dexamethasone; VTDC, bortezomib plus thalidomide plus dexamethasone plus cyclophosphamide; TAD, thalidomide plus doxorubicin plus dexamethasone. 
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Conclusion
The NMA demonstrated that the VTD, VTDC, and TAD regimens are most beneficial in terms of ORR, OS, and PFS for transplant-eligible patients with NDMM, respectively.
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